Revenue + Forward P/E
Roivant Sciences Ltd. (ROIV) quarterly revenue and forward P/E
RevenueRevenue (est)Forward P/E
Valuation
Market cap
$26.23B
Enterprise value
$23.67B
P/E ratio (TTM)
-76.87x
P/S ratio (TTM)
3025.18x
P/B ratio
5.36x
EV/Sales
2865.90x
EV/EBITDA
-90.62x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$8.26M
Gross profit (TTM)
$6.97M
Operating income (TTM)
$-1.29B
EBITDA (TTM)
$-261.23M
Net income (TTM)
$-299.77M
Free cash flow (TTM)
$-758.56M
Margins & returns
Gross margin
84.44%
Operating margin
-15560.57%
Profit margin
-3629.19%
Return on equity
-6.85%
Return on assets
-5.23%
Per-share metrics
EPS (TTM)
-$0.43
Dividend yield
0.00%
Beta
1.11
Capital structure
Cash & equivalents
$1.42B
Total debt
$107.44M
Net debt
$-1.32B
Shares outstanding
722.41M
Financial health
Current ratio
18.37
Debt / equity
0.02
Debt / assets
0.02
Interest coverage
-
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $629.92B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $442.26B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.22B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $355.30B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.86B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $26.23B | -76.87x | 3025.18x | -90.62x | - |